Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.34 |
| ▸ | BDNF | P23560 | 3/20 | 0.33 |
| ▸ | PTN | P21246 | 2/20 | 0.33 |
| ▸ | MDK | P21741 | 2/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | BMP2 | P12643 | 2/20 | 0.31 |
| ▸ | VEGFA | P15692 | 2/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.31 |
| ▸ | SHH | Q15465 | 2/20 | 0.31 |
| ▸ | IFNG | P01579 | 1/20 | 0.31 |
| ▸ | PF4 | P02776 | 1/20 | 0.31 |
| ▸ | CCL2 | P13500 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
| ▸ | BMP6 | P22004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26478722 | 0.90 | BDNF (0.39) | LGALS3LGALS8LGALS4BDNFPTN | |
| SCHEMBL26478665 | 0.90 | LGALS3 (0.34) | LGALS3LGALS8LGALS4BDNFPTN | |
| SCHEMBL26478783 | 0.90 | BDNF (0.39) | LGALS3LGALS8LGALS4BDNFPTN | |
| SCHEMBL25885710 | 0.84 | — | — | |
| SCHEMBL26478775 | 0.83 | BDNF (0.35) | LGALS3LGALS8LGALS4BDNFPTN | |
| SCHEMBL22137175 | 0.83 | LGALS3 (0.42) | LGALS3LGALS8LGALS4BDNFPTN | |
| SCHEMBL26478813 | 0.80 | BDNF (0.34) | LGALS3LGALS8LGALS4BDNFPTN | |
| SCHEMBL26479163 | 0.80 | MDK (0.45) | LGALS3LGALS8LGALS4BDNFPTN | |
| SCHEMBL26478817 | 0.79 | BDNF (0.33) | BDNFPTNMDKHPSEBMP2 | |
| SCHEMBL25885712 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642415-B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | ASCENDIS PHARMA A/S (DK) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11642415-B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | CD44, HCAR3, HPSE | LGALS3 547/4885LGALS8 674/4885LGALS4 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.